Merck & Co. has scored an FDA approval for its blockbuster-to-be Welireg to move into second-line treatment of kidney cancer, ...
From its original U.S. home base in Deerfield, Illinois, Lundbeck now plans to relocate its local headquarters to Greater ...
Bristol Myers Squibb plans another major round of job cuts in New Jersey, bringing the number of total layoffs the company ...
Eli Lilly and InnoCare Pharma inked a multi-target deal potentially worth $3.35 billion. The FDA has doled out the first approval for a novel cancer drug from a Korean company. | Eli Lilly and ...
Much like GSK (formerly GlaxoSmithKline) and the once Sanofi-Aventis (now just Sanofi), Novo Nordisk is slimming down its ...
Roche’s T-cell engager portfolio has notched another milestone, as a phase 3 trial of the company’s Lunsumio met its primary ...
A U.K. watchdog has scolded Eli Lilly over a press release the drugmaker sent to the BBC, arguing that its use of ...
Par Health has issued a voluntary recall of two lots of the IV sedative dexmedetomidine HCl in 0.9% sodium chloride injection ...
Novo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to ...
In just over a month, the FDA has cleared not one, but two treatments for fibrodysplasia ossificans progressiva (FOP), an ultra-rare genetic condition that causes soft tissues to turn to bone. | Mirum ...
In their lawsuit, BMS and Ono accuse Amgen of aiming to market its biosimilar ahead of the expiration of key U.S. patents ...
Consumer drug behemoth Reckitt is dropping $600 million on a multi-year revamp of its U.S. operations. The health and hygiene ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results